Chinook Therapeutics, Inc.
KDNYDelisted Aug 11, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001435049
Chinook Therapeutics, Inc. was delisted on Aug 11, 2023; its insiders filed their last Form 4 on Aug 11, 2023; 185 institutions reported holding it in 13F filings for Q2 2023, worth $2.24B in total; no superinvestor held it.
Holders of 5% or more of KDNY
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Chinook Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Chinook Therapeutics, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
23 Schedule 13D and 13G filings on Chinook Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 22, 2023 | Samsara BioCapital, L.P. | 13D/AOld format | – | – | – | SEC |
| Aug 11, 2023 | Farallon Capital Partners, L.P. | 13DOld format | – | New | – | SEC |
| Aug 1, 2023 | Baillie Gifford & Co | 13G/AOld format | – | – | – | SEC |
| Mar 10, 2023 | Versant Venture Capital VII, L.P. | 13D/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Frazier Life Sciences Public Fund, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Deep Track Capital, LP | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Point72 Asset Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 1, 20234:54 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Dec 28, 2022 | Versant Venture Capital VII, L.P. | 13D/AOld format | – | – | – | SEC |
| Aug 22, 2022 | Versant Venture Capital VII, L.P. | 13D/AOld format | – | – | – | SEC |
| Jun 7, 2022 | Point72 Asset Management, L.P. | 13GOld format | – | New | – | SEC |
| Jun 1, 2022 | Samsara BioCapital, L.P. | 13DOld format | – | New | – | SEC |
| Apr 29, 2022 | Frazier Life Sciences Public Fund, L.P. | 13GOld format | – | New | – | SEC |
| Apr 13, 2022 | Versant Venture Capital VII, L.P. | 13D/AOld format | – | – | – | SEC |
| Feb 22, 2022 | Morningside Venture (VI) Investments Ltd | 13D/AOld format | – | – | – | SEC |
| Feb 16, 2022 | Deep Track Capital, LP | 13GOld format | – | New | – | SEC |
| Feb 4, 20224:12 PM ET | BlackRock Inc. | 13GOld format | – | New | – | SEC |
| Jan 21, 2022 | ATP Life Science Ventures, L.P. | 13G/AOld format | – | – | – | SEC |
| Jan 13, 2022 | Versant Venture Capital VII, L.P. | 13D/AOld format | – | – | – | SEC |
| Sep 7, 2021 | Versant Venture Capital VII, L.P. | 13D/AOld format | – | – | – | SEC |
| Feb 16, 20214:20 PM ET | Morningside Venture (VI) Investments Ltd | 13D/AOld format | – | – | – | SEC |
| Feb 12, 2021 | Vivo Capital IX, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2021 | Renaissance Technologies LLC | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Chinook Therapeutics, Inc. shares.
No Form 144 notices for Chinook Therapeutics, Inc. are on file.